Get the Stockscreener App
3.07
2.54%
-0.08
After Hours:
3.11
0.04
+1.30%
Sana Biotechnology Inc stock is traded at $3.07, with a volume of 4.18M.
It is down -2.54% in the last 24 hours and down -16.80% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
See More
Previous Close:
$3.15
Open:
$3.19
24h Volume:
4.18M
Relative Volume:
1.26
Market Cap:
$854.36M
Revenue:
-
Net Income/Loss:
$-244.17M
P/E Ratio:
-3.1445
EPS:
-0.9763
Net Cash Flow:
$-144.77M
1W Performance:
+0.00%
1M Performance:
-16.80%
6M Performance:
-6.69%
1Y Performance:
+53.50%
1-Day Range:
$3.06
$3.245
1-Week Range:
$2.91
$3.245
52-Week Range:
$1.94
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.07 | 876.62M | 0 | -244.17M | -144.77M | -0.9763 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Wedbush | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
RA Capital affiliates report 18.75M Sana Biotechnology shares (NASDAQ: SANA) - Stock Titan
Sana Biotechnology | SCHEDULE 13G: Others - Moomoo
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $3.07 - Moomoo
InvestingPro Fair Value spotted Sana Biotech overvaluation early By Investing.com - Investing.com Canada
Sana Biotechnology raises $69M through ATM share sale - MSN
Sana Biotech rises as Mayo Clinic partners for diabetes therapy - MSN
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility - Moomoo
Sana Biotechnology Raises $69 Million Through Equity Offering - TipRanks
Sana Biotechnology (SANA) sells 21.6M shares to raise about $69M - Stock Titan
Sana Biotechnology | 8-K: Current report - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sana Biotechnology Raises $69 Million Through ATM Equity Offering - Moomoo
Sana Biotechnology raises $69 million through stock sale By Investing.com - Investing.com Australia
Sana Biotechnology raises $69 million through stock sale - Investing.com
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through Its At-the-Market (ATM) Facility - 富途牛牛
SANA Stock Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Sana presents preclinical data on in vivo CAR T therapy SG293 - Investing.com UK
Sana presents preclinical data on in vivo CAR T therapy SG293 By Investing.com - Investing.com India
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
SANA: Progress in gene-edited islet and in vivo CAR-T therapies positions the pipeline for major milestones - TradingView
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs - The Manila Times
Sana Biotechnology Presents Preclinical Data for In Vivo - GlobeNewswire
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $16 - Moomoo
Sana Biotechnology | 10-Q: Q1 2026 Earnings Report - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss By Investing.com - Investing.com South Africa
Sana Biotechnology | 8-K: Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss - Investing.com India
Sana: Q1 Earnings Snapshot - kare11.com
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q1 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.16 - marketscreener.com
Sana Biotechnology | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Sana Biotechnology (SANA) Q1 2026 loss widens cash risk despite Mayo deal - Stock Titan
Mayo collaboration and Q1 2026 results for Sana (NASDAQ: SANA) - Stock Titan
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - ChartMill
Rodman & Renshaw initiates Sana Biotechnology stock with buy rating - Investing.com
Rodman & Renshaw initiates Sana Biotechnology stock with buy rating By Investing.com - Investing.com Canada
Is Sana Biotechnology’s (SANA) Options Spike Before Earnings Hinting at a Repriced Cell Therapy Story? - simplywall.st
Sana Biotechnology (SANA) Valuation Check As Conference Update And Partnerships Keep Investor Focus High - Sahm
MSN Money - MSN
Sana Biotechnology (SANA) Investor Outlook: A 144.90% Upside Potential In Innovative Cell Therapy - DirectorsTalk Interviews
Sana Biotechnology (SANA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Sana CEO Steve Harr to give business update in May 12 webcast - Stock Titan
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference - The Manila Times
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):